Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

octapharma pharmazeutika produktionsges. m.b.h. - albumin human - solution for i/v infusion - 50mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

octapharma pharmazeutika produktionsges. m.b.h. - albumin human - solution for i/v infusion - 200mg/ml

United States - English - NLM (National Library of Medicine)

octapharma usa inc - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t), prothrombin (unii: 8fb1k07f16) (prothrombin - unii:8fb1k07f16), coagulation factor vii human (unii: 4156xvb4qd) (coagulation factor vii human - unii:4156xvb4qd), coagulation factor x human (unii: 0p94uqe6sy) (coagulation factor x human - unii:0p94uqe6sy), protein c (unii: 3z6s89txpw) (protein c - unii:3z6s89txpw), protein s human (unii: 90j3f6n5fn) (protein s human - unii:90j3f6n5fn) - balfaxar (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin k antagonist (vka, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure. - known anaphylactic or severe systemic reactions to balfaxar or any of the components of the product. for a complete listing of ingredients, [ see description ( 11 ) ]. - known allergy to heparin or history of heparin-induced thrombocytopenia (hit). - iga deficient patients with known antibodies against iga. risk summary there are no data with balfaxar use in pregnancy to inform on drug-associated risk. animal reproduction studies have not been conducted with balfaxar. it is not known whether balfaxar can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. in the u.s. general population, the estimated background risk of major birth defects and miscarriage

Malta - English - Malta Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human normal, immunoglobulin - solution for injection - human normal immunoglobulin 165 mg - immune sera and immunoglobulins

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - human normal immunoglobulin - solution for injection - 165 milligram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for extravascular adm.

United Kingdom - English - myHealthbox

octapharma limited - human coagulation factor viii, willebrand factor (vwf:rco) - powder and solvent for solution for injection - 500iu, 60iu - antihemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

United Kingdom - English - myHealthbox

octapharma limited - human coagulation factor viii, willebrand factor (vwf:rco) - powder and solvent for solution for injection - 200iu, 120iu - antihemorrhagics: blood coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

United States - English - NLM (National Library of Medicine)

octapharma pharmazeutika produktionsgesellschaft m.b.h. - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk), von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - antihemophilic factor human 100 [iu] in 1 ml - wilate is a von willebrand factor/coagulation factor viii complex (human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von willebrand disease (vwd) as well as patients with mild or moderate vwd in whom the use of desmopressin is known or suspected to be ineffective or contraindicated. clinical trials to evaluate the safety and efficacy of prophylactic dosing with wilate to prevent spontaneous bleeding have not been conducted in vwd subjects. wilate is not indicated for the prevention of excessive bleeding during and after surgery in vwd patients. wilate is not indicated for hemophilia a. wilate is contraindicated for patients who have known anaphylactic or severe systemic reaction to plasma-derived products, any ingredient in the formulation, or components of the container. for a complete listing of ingredients, see description ( 11 ). pregnancy category c. animal reproduction studies have not been conducted with wilate. it is also not known whether

United States - English - NLM (National Library of Medicine)

octapharma ab - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - human immunoglobulin g 50 mg in 1 ml - octagam is an immune globulin intravenous (human) 5% liquid indicated for treatment of primary humoral immunodeficiency (pi), such as congenital agammaglobulinemia, common variable immunodeficiency, x-linked agammaglobulinemia, wiskott-aldrich syndrome and severe combined immunodeficiencies. octagam 5% liquid is contraindicated in patients who have acute severe hypersensitivity reactions to human immunoglobulin. octagam 5% liquid contains trace amounts of iga (not more than 0.2 mg/ml in a 5% solution). it is contraindicated in iga deficient patients with antibodies against iga and history of hypersensitivity (see description [11]). octagam 5% liquid is contraindicated in patients with acute hypersensitivity reaction to corn. octagam 5% liquid contains maltose, a disaccharide sugar which is derived from corn. patients known to have corn allergies should avoid using octagam 5% liquid. pregnancy category c. animal reproduction studies have not been conducted with octagam 5% liquid. it is also not known whether o

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - human immunoglobulin g, quantity: 100 mg/ml - injection - excipient ingredients: octoxinol 10; maltose; tributyl phosphate; water for injections; human immunoglobulin a - replacement therapy in: primary immunodeficiency syndromes: congenital agammaglobulinaemia and hypogammaglobulinaemia; common variable immunodeficiency; severe combined immunodeficiencies; wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital acquired immune deficiency syndrome (aids) who have repeated bacterial infections; immunomodulation: idiopathic thrombocytopenic purpura, in adults or children with a high risk of bleeding or prior to surgery to correct platelet count. guillain barre syndrome. kawasaki disease. allogeneic bone marrow transplantation.